Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
EpiCept to Report Fourth Quarter and Full Year 2008 Operating and Financial Results on February 27, 2009 TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Regulatory News: EpiCept Corporation (Nasdaq and OMX...
-
EpiCept Announces Debt Repayment TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today that it has repaid the outstanding...
-
EpiCept Announces EPC2407 Generic Name is Crinobulin TARRYTOWN, N.Y.--(BUSINESS WIRE)-- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that the United States Adopted...
-
EpiCept Corporation to Present at the 11th Annual BIO CEO & Investor Conference TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today...
-
EpiCept Corporation Announces Pricing of Public Offering TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today the pricing...
-
EpiCept Announces Resignation of Board Member TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced that John F. Bedard has...
-
EpiCept Receives Permission to File Ceplene® NDA No New Pivotal Clinical Data Required for Submission NDA Filing Expected Second Half of This Year TARRYTOWN, N.Y.--(BUSINESS WIRE)-- EpiCept...
-
EpiCept Announces Positive Results from Phase IIb Trial for EpiCeptTM NP-1 All Primary Endpoints Met, Efficacy Superior to Placebo, Equivalent to Gabapentin TARRYTOWN, N.Y.--(BUSINESS...
-
EpiCept Discontinues Drug Discovery Operations and Reduces Workforce Resources to Focus on Ceplene® and Clinical Pipeline TARRYTOWN, N.Y.--(BUSINESS WIRE)-- EpiCept Corporation (Nasdaq and OMX...
-
EpiCept Announces Substantial Debt Reduction TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today that as a result of the...